Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

A-095

Supelco

Atomoxetine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)
Empirical Formula (Hill Notation):
C17H22ClNO
CAS Number:
82248-59-7
Molecular Weight:
291.82
EC Number:
200-659-6
MDL number:
MFCD06410992
UNSPSC Code:
41116107
PubChem Substance ID:
329770640
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

Cl.CNCC[C@@H](Oc1ccccc1C)c2ccccc2

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

InChI key

LUCXVPAZUDVVBT-UNTBIKODSA-N

Gene Information

human ... SLC6A2(6530)

Related Categories

General description

Atomoxetine is an attention-deficit hyperactivity disorder (ADHD) drug marketed in the US under the trade name Strattera®. This Certified Spiking Solution® is suitable for use in numerous testing applications such as clinical toxicology, forensic analysis, pharmaceutical research, urine drug testing, or calibrator preparation.

Application


  • Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine.: This study investigates the metabolic pathways and profiles of atomoxetine, highlighting its pharmacokinetic properties. The research underscores the significance of Atomoxetine HCl solution in understanding the drug′s metabolism and its implications for ADHD treatment (MacKenzie et al., 2020).


  • Using Cell Cultures for the Investigation of Treatments for Attention Deficit Hyperactivity Disorder.: This systematic review explores the use of cell cultures in studying ADHD treatments, including atomoxetine. It provides insights into the cellular mechanisms and efficacy of Atomoxetine HCl, demonstrating its role in advancing ADHD pharmacological research (Chierrito et al., 2019).



Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Strattera is a registered trademark of Eli Lilly and Co.

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

WGK

WGK 1

Flash Point(F)

49.5 °F

Flash Point(C)

9.7 °C

Regulatory Information

危险化学品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Michael Turner et al.
Behavioural brain research, 243, 28-37 (2012-12-26)
Atomoxetine (ATX) is a commonly used non-stimulant treatment for Attention deficit hyperactivity disorder (ADHD). It primarily acts to increase noradrenalin levels; however, at higher doses it can increase dopamine levels. To date there has been no investigations into the effects
Dongyi Tony Du et al.
Medical care, 50(11), 987-992 (2012-10-11)
The Food and Drug Administration (FDA) issued a Public Health Advisory entitled "Suicidal Thinking in Children and Adolescents Being Treated with Strattera (Atomoxetine)" on September 29, 2005. At FDA's request, the manufacturer subsequently added a boxed warning to the drug's
Emilia Marchei et al.
Drug testing and analysis, 5(3), 191-195 (2012-09-20)
Atomoxetine (ATX) is a selective norepinephrine reuptake inhibitor approved since 2002 for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults as an alternative treatment to methylphenidate. Within the framework of a project evaluating the use
Hedi Schelleman et al.
PloS one, 8(1), e52991-e52991 (2013-02-06)
To compare the incidence rates of serious cardiovascular events in adult initiators of amphetamines or atomoxetine to rates in non-users. This was a retrospective cohort study of new amphetamines (n=38,586) or atomoxetine (n=20,995) users. Each medication user was matched to
M Reza Mirbolooki et al.
Synapse (New York, N.Y.), 67(2), 79-93 (2012-10-20)
Brown adipose tissue (BAT) plays a significant role in metabolism. In this study, we report the use of atomoxetine (a clinically applicable norepinephrine reuptake inhibitor) for (18)F-FDG PET imaging of BAT and its effects on heat production and blood glucose
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service